ライフサイエンスコーパス: anti-tumor activity

1 rategy for producing targeted and long-lived anti-tumor activity.

2 ion contributes to BET bromodomain inhibitor anti-tumor activity.

3 reduced incidence of acute GvHD yet retained anti-tumor activity.

4 t to one favoring acute responses and potent anti-tumor activity.

5 is a transcription factor that has apoptotic anti-tumor activity.

6 beta-sheet peptide with anti-angiogenic and anti-tumor activity.

7 h various approaches, with a clear signal of anti-tumor activity.

8 describe surrogate endpoints correlated with anti-tumor activity.

9 proteins, suggesting that TIMPs may possess anti-tumor activity.

10 elds highly aggressive tumors with decreased anti-tumor activity.

11 In some instances it may also have direct anti-tumor activity.

12 strategies that are designed to augment TIL anti-tumor activity.

13 termine if molecular context associates with anti-tumor activity.

14 umor efficacy via FAS mediated CD8(+) T cell anti-tumor activity.

15 ics (PK), pharmacodynamic (PD) activity, and anti-tumor activity.

16 superior tissue infiltration, stemness, and anti-tumor activity.

17 giogenic efficacy of Bev and its concomitant anti-tumor activity.

18 iers in the tumor microenvironment attenuate anti-tumor activity.

19 hing exposure well above the requirement for anti-tumor activity.

20 that therapeutic targeting of ZEB2 exhibits anti-tumor activity.

21 e event causality, pharmacokinetics (PK) and anti-tumor activity.

22 ng IL-12, IL-27 and GM-CSF, and tested their anti-tumor activity.

23 as a succinyltransferase for PD-L1, boosted anti-tumor activity.

24 a HCC xenograft mouse model led to enhanced anti-tumor activity.

25 rd M1-like state in mice, and exhibit potent anti-tumor activity.

26 ctively induces DR5 clustering, resulting in anti-tumor activity.

27 including EGFR or PI3Kalpha, led to enhanced anti-tumor activity.

28 uation of safety, highest tolerated dose and anti-tumor activity.

29 ses (IDHs), was recently reported to exhibit anti-tumor activity.

30 Secondary endpoints included anti-tumor activity.

31 mitochondrial metabolism and enhances their anti-tumor activity.

32 the emergence of drug resistance limits its anti-tumor activity.

33 uitination assay, likely stabilizing p53 for anti-tumor activity.

34 L1 blocking activity and significant in vivo anti-tumor activity.

35 of CD69(+)CD103(+) Trm-like TIL and limited anti-tumor activity.

36 production through the HDAd further enhances anti-tumor activity.

37 Thus, the BAD(3SA) mutation unmasked latent anti-tumor activity.

38 other mechanisms contribute to perifosine's anti-tumor activity.

39 al medicine and has been observed to contain anti-tumor activity.

40 n the TME to realize synergistic or additive anti-tumor activity.

41 and tumor cell apoptosis and showed superior anti-tumor activity.

42 ibodies to OX40 and other TNFR with improved anti-tumor activity.

43 cell metabolic activity and thereby modulate anti-tumor activity.

44 FcgammaR-binding capacity compromises their anti-tumor activity.

45 RF7/IFNbeta pathway was required for optimal anti-tumor activity.

46 synergizes with carfilzomib and shows potent anti-tumor activity.

47 idely used anti-diabetic drug with potential anti-tumor activity.

48 anti-PD-ligand 1 (L1) Abs for their optimal anti-tumor activity.

49 perties, which give it immunosuppressant and anti-tumor activity.

50 tion of these enzymes has been shown to have anti-tumor activity.

51 rms of immunity contribute to complete apoA1 anti-tumor activity.

52 equired for an optimal alpha-GalCer-mediated anti-tumor activity.

53 r-expressed tumors can further enhance their anti-tumor activity.

54 ains of mice, yet retains full cytotoxic and anti-tumor activities.

55 one modification profiles, and with specific anti-tumor activities.

56 ng investigated in clinical trials for their anti-tumor activities.

57 of MAP30, a plant protein with anti-HIV and anti-tumor activities.

58 pathway that contributes to MAP30's anti-HIV/anti-tumor activities.

59 pharmaceutical agents with antimicrobial and anti-tumor activities.

60 cells, including enhanced antimicrobial and anti-tumor activities.

61 ive anti-inflammatory, immunosuppressive and anti-tumor activities.

62 orated in DOPC nanoliposomes, we demonstrate anti-tumor activities.

63 cargos to immune recipient cells, inhibiting anti-tumor activities.

64 of them, show specific anti-inflammatory and anti-tumor activities.

65 e cytokines with potent immunomodulating and anti-tumor activities.

66 nhibits MEK1/2 phosphorylation, and exhibits anti-tumor activities across multiple models carrying KR

67 umor silencing of KRAS(G12V) and significant anti-tumor activity across several cancer models.

68 ersatile allogeneic cell therapy with potent anti-tumor activity, acting at the interplay between inn

69 olated death ligand that possesses selective anti-tumor activity against a number of cancer cell line

70 is a novel cytotoxic agent with exceptional anti-tumor activity against a range of human and murine

71 a topoisomerase I (TOP1) inhibitor, exhibits anti-tumor activity against a wide range of tumors.

72 NO-Cbl and Apo2L/TRAIL exerted synergistic anti-tumor activity against A375 xenografts.

73 Anti-tumor activity against breast cancer cell lines (MC

74 PARP inhibition (PARPi) has anti-tumor activity against castration-resistant prostat

75 ABBV-303 demonstrated anti-tumor activity against established xenografts in CD

76 quinol derivative that exhibits significant anti-tumor activity against human breast, colon, and ren

77 bility, and has acquired proof of concept of anti-tumor activity against low-grade serous ovarian can

78 nces oral absorption of DIM-14 and increased anti-tumor activity against lung tumor models.

79 ll molecule inhibitor (NSC33353) with potent anti-tumor activity against TNBC cells.

80 Serious adverse reactions, moderate anti-tumor activity, allergen withdrawal, antigen escape

81 Therefore, neoadjuvant TNT shows promising anti-tumor activity and acceptable toxicity.

82 The latter gradually lose their anti-tumor activity and acquire an epigenetically fixed,

83 or-localized activation of STING for greater anti-tumor activity and better tolerability.

84 agonist platform induced robust and durable anti-tumor activity and demonstrated high stability and

85 n effective strategy to enhance the avidity, anti-tumor activity and functional memory formation of T

86 co-stimulatory domain as a driver of potent anti-tumor activity and IFNgamma secretion.

87 ed PCa were enrolled to evaluate the safety, anti-tumor activity and immunogenicity of enoblituzumab

88 of PA-L1-I207R and PA-U2-R200A showed potent anti-tumor activity and low toxicity, exceeding the perf

89 K) cells are innate immune cells with strong anti-tumor activity and may offer a promising treatment

90 By contrast, GzB-IL18 promotes anti-tumor activity and myeloid cell re-programming with

91 d in vivo with S protein vaccines to enhance anti-tumor activity and persistence.

92 o STING activation in tumors, with increased anti-tumor activity and reduced serum cytokine elevation

93 cells via D-mannose supplementation enhances anti-tumor activity and restricts exhaustion differentia

94 Anti-tumor activity and selectivity of Dp44mT in Pgp-exp

95 on of apoptosis by XK469 may account for its anti-tumor activity and such activity is required for th

96 mor cell-extrinsic contributors to sotorasib anti-tumor activity and suggest that early on-treatment

97 l inhibitory Ly49 receptors restores NK cell anti-tumor activity and targeted T-cell lymphoma elimina

98 We evaluated anti-tumor activity and toxic effect of an adenoviral ve

99 -malaria drug that has been shown to exhibit anti-tumor activity, and functional lysosomes are report

100 CAR-neutrophils with the best anti-tumor activity are produced to specifically and non

101 nd GM-CSF or IL-2 DNA resulted in equivalent anti-tumor activity as E2.

102 o of these inhibitors, PD98059 and TPCK, had anti-tumor activity as single agents in both zebrafish e

103 (HIF2A) is of central importance to miR-182 anti-tumor activity, as it results in enhanced therapy s

104 ase inhibitors is insufficient for effective anti-tumor activity because the reactivation of the ErbB

105 the tumor microenvironment to maximize their anti-tumor activity before progressing to irreversible d

106 lin-expressing cancers given its encouraging anti-tumor activity, but it may have a narrow therapeuti

107 rus type 5 E1A protein (E1A) associates with anti-tumor activities by reversing the transformed pheno

108 on phase 1 trial, the potential for improved anti-tumor activity by combining amivantamab, an EGFR-ME

109 ung tumor cells while stimulating CAR-T cell anti-tumor activity by release of IL-12 and PD-L1 blocke

110 ype III interferons, which contribute to the anti-tumor activity by upregulating type I interferon an

111 ), a cell-permeable, small molecule that has anti-tumor activity, can also activate NOD1 and NOD2.

112 uperior prolonged persistent and invigorated anti-tumor activities compared to the optimized FGFR4-sp

113 ST738), EC2629 showed significantly greater anti-tumor activity compared to their corresponding stan

114 This defect in anti-tumor activity correlated with two known age-associ

115 ing hCD19 resulted in significant additional anti-tumor activity, demonstrating the feasibility of ge

116 This anti-tumor activity depended on trametinib-mediated Id1

117 portant role for type III interferons in the anti-tumor activity elicited by STING agonism and provid

118 NECTIN4-CAR T cells have potent anti-tumor activity even against EV resistant cells, whi

119 and adaptive immune response and potentiate anti-tumor activity for immunotherapies to treat cancer.

120 CLDC-based delivery also identified a novel anti-tumor activity for the metastasis suppressor gene C

121 A better understanding of how to uncouple anti-tumor activity from loss of self-tolerance is neces

122 ned delivery of these genes did not increase anti-tumor activity, further suggesting that each gene a

123 ccines designed to elicit CTL responses with anti-tumor activity has become a reality thanks to the i

124 Anti-tumor activity has been demonstrated with monoclona

125 r and molecular mechanisms of IL-12-mediated anti-tumor activity have been examined.

126 ble tool to simultaneously evaluate the drug anti-tumor activity, hepatotoxicity and pharmacokinetics

127 Moreover, MPD3 elicited robust anti-tumor activities in both local and liver metastatic

128 how that apoptosis plays a key role in their anti-tumor activities in colon cancer cells and xenograf

129 small-molecule inhibitors of SKP2 exhibited anti-tumor activities in vivo and in OS organoids as wel

130 ng other IgG1 and IgG2 mAbs to DR4 for their anti-tumor activities in vivo.

131 cutaneous AIDS-KS tumors caused considerable anti-tumor activity in a dose-dependent manner, with hig

132 r polymer conjugated to SN-38 was tested for anti-tumor activity in a HER2-positive gastric cancer xe

133 , our data prove that poly I:C has potential anti-tumor activity in a mouse model of established pulm

134 This multiantigen vaccine shows anti-tumor activity in a murine model of prostate cancer

135 b, a proteasome inhibitor, shows substantial anti-tumor activity in a variety of tumor cell lines, is

136 Although IL-9 has potent anti-tumor activity in adoptive cell transfer therapy, s

137 rrent CDK4/6 inhibitors, and providing broad anti-tumor activity in aggressive cancer types like TNBC

138 infiltration, and augmentes immune-dependent anti-tumor activity in an LKB1-mutant immune-competent m

139 dose-dependent in vivo CARM1 inhibition and anti-tumor activity in an MM xenograft model.

140 ermore, inhibitors of NF-kappaB demonstrated anti-tumor activity in androgen deprivation-resistant pr

141 TRuC-T cells demonstrate potent anti-tumor activity in both liquid and solid tumor xenog

142 al studies have demonstrated that EPA exerts anti-tumor activity in breast cancer.

143 A p53 rescue motif peptide exhibits an anti-tumor activity in cancer cell lines expressing wild

144 -ODN (800 ng) formulations and evaluated its anti-tumor activity in combination with anti-PD-1 therap

145 Consequently, Dp44mT has greater anti-tumor activity in drug-resistant relative to non-Pg

146 olecule inhibitors against EZH2 demonstrated anti-tumor activity in EZH2-mutated lymphomas and entere

147 R-2HG also displays anti-tumor activity in glioma.

148 well tolerated and demonstrated preliminary anti-tumor activity in heavily pre-treated patients, sug

149 ro-inflammatory phenotypes. IgE demonstrates anti-tumor activity in human melanoma xenograft models e

150 NG-driven innate immunity to promote durable anti-tumor activity in humans.

151 ATRi shows enhanced anti-tumor activity in LKB1 and/or KEAP1-deficient non-s

152 nts targeting Her2 have not yet demonstrated anti-tumor activity in MIBC.

153 tance to LCN2 and significantly improved the anti-tumor activity in mice.

154 t antisense MDM2 inhibitors have significant anti-tumor activity in multiple human cancer models with

155 Overall, IMA203 showed promising anti-tumor activity in multiple solid tumors, including

156 To gain insight into perifosine anti-tumor activity in neuroblastoma we have studied cha

157 Due to its strong anti-tumor activity in only certain histotypes, several

158 atment option with rapid, robust and durable anti-tumor activity in patients with diverse RET fusion-

159 Regorafenib has anti-tumor activity in patients with unresectable hepato

160 antibody has recently been reported to have anti-tumor activity in preclinical models.

161 inds a unique CD38 epitope and showed strong anti-tumor activity in preclinical models.

162 available Notch-blocking agents are showing anti-tumor activity in preclinical studies, they are not

163 nd cancer-associated fibroblasts, had potent anti-tumor activity in primary short-term cultures and p

164 otein has membrane-disrupting properties and anti-tumor activity in several cancer animal models.

165 merging studies show that it displays potent anti-tumor activity in several human cancers.

166 The resulting CARs display enhanced anti-tumor activity in several RMS xenograft models exce

167 ed at doses that have resulted in impressive anti-tumor activity in several types of refractory neopl

168 ubstituted DNMTi that has been shown to have anti-tumor activity in solid tumor models.

169 T cell trafficking, persistence, and durable anti-tumor activity in solid tumors.

170 Selective anti-tumor activity in the absence of toxicity provides

171 clinical trial, HRS-4642 exhibited promising anti-tumor activity in the escalating dosing cohorts.

172 + BET bromodomain inhibition led to additive anti-tumor activity in the most resistant cell lines.

173 al of targeting CAFs to restore fibroblastic anti-tumor activity in the pancreatic microenvironment.

174 ed in patient samples and provided effective anti-tumor activity in the presence of anti-cell IgG in

175 (Iressa) and erlotinib (Tarceva) have shown anti-tumor activity in the treatment of non-small cell l

176 small molecule inhibitor, NSC33353, exhibits anti-tumor activity in TNBC cells, and works in a synerg

177 bitors of DYRK2 exhibit in vitro and in vivo anti-tumor activity in triple-negative breast cancer and

178 py, but also significantly ameliorates CAR T anti-tumor activity in various mouse tumor models.

179 kt membrane translocation and that API-1 has anti-tumor activity in vitro and in vivo and could be a

180 by mono- or multi-valent T cells have potent anti-tumor activity in vitro and in vivo with significan

181 ), produces potent and highly CD30-selective anti-tumor activity in vitro and in vivo.

182 c pathways to enhance CAR T cell fitness and anti-tumor activity in vitro and in vivo.

183 cells/tissues, leading to a higher level of anti-tumor activity in vitro and in vivo.

184 IMV-M demonstrated potent, MUC16-selective anti-tumor activity in vitro and in xenograft models wit

185 This may greatly improve TIL persistence and anti-tumor activity in vivo after adoptive transfer into

186 n therapies involving CX-5461 have promising anti-tumor activity in vivo in neuroblastoma, our identi

187 annoma cells in culture and displayed potent anti-tumor activity in vivo, impairing schwannoma develo

188 ff-target reactivity while maintaining their anti-tumor activity in vivo, thus showing that complete

189 l strength to an intermediate range improved anti-tumor activity in vivo.

190 their biodistribution, serum half-life, and anti-tumor activity in vivo.

191 lly stable in liver microsomes and displayed anti-tumor activity in xenograft mouse cancer models.

192 nt BiTE protein at doses required to achieve anti-tumor activity, induced systemic inflammatory respo

193 gle antigen vaccine demonstrated significant anti-tumor activity inhibiting growth of implanted Myc-C

194 in vivo angiogenesis assays showed that this anti-tumor activity is due largely to the indirect targe

195 Their anti-tumor activity is further enhanced by in vivo co-st

196 een discovered and the scope of p53-mediated anti-tumor activity is largely expanded.

197 In vivo, MCLA-145 anti-tumor activity is superior to immune checkpoint inh

198 that a potential mechanism of rhIL-2/rmIL-12 anti-tumor activity is the inhibition of neovascular gro

199 d the analogs as novel SHP-1 inhibitors with anti-tumor activity likely via an immune mechanism, supp

200 Cabozantinib plus durvalumab demonstrated anti-tumor activity, manageable toxicity, and have led t

201 The nanobioconjugate exhibited marked anti-tumor activity manifested by significantly longer a

202 Additionally, their anti-tumor activity may be enhanced by targeting BTG1.

203 This study evaluates its anti-tumor activity, mechanism of action, ability to tre

204 initially came to prominence because of its anti-tumor activity, most attention is now focused on it

205 ermore, the MMP-activated LT had very potent anti-tumor activity not only to human melanomas containi

206 which plays a mechanistic role in mediating anti-tumor activities of HER2-directed therapies.

207 phoma, recently, we and others have reported anti-tumor activities of IL-9 in melanoma mediated by ma

208 Our results indicate that harnessing the anti-tumor activities of miR-182 via safe and robust del

209 anisms have been proposed to account for the anti-tumor activities of therapeutic antibodies, includi

210 sted that the antiproliferative and possibly anti-tumor activities of these compounds are linked to t

211 proaches discovered recently can augment the anti-tumor activities of TNFR antibodies by enhancing th

212 ify miR-498 as an important mediator for the anti-tumor activity of 1,25(OH)(2)D(3).

213 The anti-tumor activity of 5-FU has been attributed in part

214 On the basis of the potent preclinical anti-tumor activity of agonist anti-GITR antibodies, rep

215 a synthetic mimics significantly enhance the anti-tumor activity of all the above-mentioned anti-canc

216 ckpoint blockade therapies, with the highest anti-tumor activity of anti-programmed death 1 (PD-1) an

217 -y and TNF-a, and significantly enhances the anti-tumor activity of antigen-specific CTLs and ROR1-ta

218 implying a critical role for B cells in the anti-tumor activity of APCP.

219 fety, pharmacokinetics, pharmacodynamics and anti-tumor activity of belzutifan were evaluated in this

220 In prostate cancer, specifically, the anti-tumor activity of BET bromodomain inhibition has be

221 Moreover, the anti-tumor activity of BET bromodomain inhibition in AR-

222 translational mechanisms, contributes to the anti-tumor activity of BET bromodomain inhibitors.

223 ty in glioblastoma lines and potentiated the anti-tumor activity of both temozolomide and ionizing ra

224 pression of Delta133p53alpha potentiates the anti-tumor activity of CD19-directed CAR T cells and lim

225 The anti-tumor activity of CD4(+) T cells did not require tu

226 immune cell function but how it affects the anti-tumor activity of CD8 T cells is not fully understo

227 This regimen empowered the anti-tumor activity of CD8(+) T cells and possessed ther

228 of CD103 enhanced the effector functions and anti-tumor activity of CD8(+) T cells, revealing a regul

229 rier to tumorigenesis and contributes to the anti-tumor activity of certain chemotherapeutic agents.

230 en used as a monotherapy, or may enhance the anti-tumor activity of chemotherapeutics, since constitu

231 (SCFAs) pentanoate and butyrate enhance the anti-tumor activity of cytotoxic T lymphocytes (CTLs) an

232 novel insight into the mechanisms underlying anti-tumor activity of E1A, but also a rationale for the

233 of glucose uptake has been implicated in the anti-tumor activity of EGFR TKIs.

234 ls with AT-101 can significantly enhance the anti-tumor activity of EGFRBi armed ATC through increase

235 Recent data demonstrating anti-tumor activity of FL suggest that this protein play

236 The anti-tumor activity of GD2-CAR.15 NKTs was assessed as a

237 microenvironment suggested that the in vivo anti-tumor activity of HDAC6i is mediated by its effect

238 In the present study we analyzed the anti-tumor activity of human IL-1 homologue 4(IL-1H4; re

239 Although the anti-tumor activity of hyaluronan-oligosaccharides, a hy

240 ies also provide convincing evidence for the anti-tumor activity of I3C, however, the molecular mecha

241 Anti-tumor activity of IGF-Ir/tf is mediated through inh

242 The anti-tumor activity of IL-1H4 was abrogated in nude and

243 The anti-tumor activity of IPI-504 was tested as both a sing

244 g inhibition is the mechanistic basis of the anti-tumor activity of isoginkgetin.

245 ing cellular cytotoxicity and apoptosis, the anti-tumor activity of mAb's might also result from acti

246 lts demonstrated for the first time that the anti-tumor activity of megestrol acetate can be enhanced

247 herapeutic use of salidroside to enhance the anti-tumor activity of neutrophils in breast cancer pati

248 We have previously demonstrated the anti-tumor activity of nitrosylcobalamin (NO-Cbl), an an

249 cancer immune-checkpoint, and increases the anti-tumor activity of NK cell infusions.

250 known about the role of K(+) channels in the anti-tumor activity of NK cells.

251 To evaluate the anti-tumor activity of p53-VP22 in vivo, we constructed

252 ion and support that phenformin improves the anti-tumor activity of PD-1 blockade immunotherapy in me

253 ma-secreting CD8(+) T cells and enhances the anti-tumor activity of PD-1 blockade in female mouse mod

254 The anti-tumor activity of recombinant mAb's directed agains

255 number and the size of tumors, revealing an anti-tumor activity of SMRAD51.

256 Here, PHY906 is reported to enhance the anti-tumor activity of Sorafenib in nude mice bearing He

257 ge could counteract PHY906 to potentiate the anti-tumor activity of Sorafenib.

258 Our findings demonstrate in vivo anti-tumor activity of SSOs that modulate Bcl-x pre-mRNA

259 id peroxidation, plays a pivotal role in the anti-tumor activity of T cell-based immunotherapies; how

260 e solid tumor and disseminated tumor models, anti-tumor activity of T cells was superior with CD28-co

261 entional therapy and delineate mechanisms of anti-tumor activity of Thal and its potent analogs (immu

262 was used to assess the BBB permeability and anti-tumor activity of the DOX-EDT-IONPs and DOX treatme

263 glioblastoma tumorigenesis, we explored the anti-tumor activity of the novel fusion protein EGF-SubA

264 tion because both the immunogenicity and the anti-tumor activity of the vaccine are blocked in mice d

265 -mediated tumor membrane repair enhances the anti-tumor activity of therapeutic antibodies in mice.

266 sing and novel approach for potentiating the anti-tumor activity of therapeutic mAb against EGFR and

267 Anti-tumor activity of these antibodies was proved using

268 ion by GA may be a critical component of the anti-tumor activity of this drug.

269 The anti-tumor activity of TIR-199 was confirmed in hollow f

270 This study was designed to assess the anti-tumor activity of topotecan (TPT) in patients with

271 This study was designed to assess the anti-tumor activity of topotecan (TPT) in patients with

272 Long-term persistence and sustained anti-tumor activity of transferred CTL, as well as respo

273 r, the biparatopic ADC demonstrates superior anti-tumor activity over ado-trastuzumab emtansine (T-DM

274 NKTR-214 shows superior anti-tumor activity over native IL-2 and systemically ex

275 Despite early signs of anti-tumor activity, patients at higher doses develop pe

276 137 agonists with these inhibitors increases anti-tumor activity preclinically, but attempts to trans

277 ll depletion, which may underlie the lack of anti-tumor activity previously observed in pre-clinical

278 posed only to the systemic drug; synergistic anti-tumor activity supported the validity of this appro

279 tion with E2A and cytE2A induced synergistic anti-tumor activity, supporting enhanced peptide present

280 dney tumor cell lines, with >250-fold higher anti-tumor activities than observed with the natural pro

281 and makes CAR-T cells that have much higher anti-tumor activity than a CAR-T that binds to shed MSLN

282 cells expressing the CAR, providing broader anti-tumor activity that arises quickly after transplant

283 establish DMF as an NFkappaB inhibitor with anti-tumor activity that may add therapeutic value in th

284 SAR'245 stimulated anti-tumor activity that was enhanced in combination wit

285 ector lymphocytes with potent anti-viral and anti-tumor activity, their interaction with muscle-deriv

286 They achieve anti-tumor activity through activating the patient's own

287 -resistant metastatic melanoma patients show anti-tumor activity through B-cell depletion by anti-CD2

288 a novel mechanism(s) by which HNK exerts its anti-tumor activity through the inhibition of c-Met-Ras-

289 cells and offer a pathway to enhancement of anti-tumor activity through their manipulation.

290 ondary objectives were to assess preliminary anti-tumor activity, to characterize camonsertib pharmac

291 Anti-tumor activity was carried out in H1650 lung tumor

292 This anti-tumor activity was dependent on IFN-gamma and CD4(+

293 Anti-tumor activity was further enhanced by appending a

294 Encouraging anti-tumor activity was noted.

295 Encouraging anti-tumor activity was observed, particularly in patien

296 contrast, the anti-PD-L1 Abs show augmented anti-tumor activity when activating FcgammaR binding is

297 Human CART117 had potent anti-tumor activity while also mediating significant hem

298 design of novel therapies exhibiting robust anti-tumor activity with limited toxicity.

299 complex microbial stimuli can elicit potent anti-tumor activity within the liver, promote cross-pres

300 ion IL-15 cytokine that can stimulate potent anti-tumor activity without severe toxicity.